Compounds > stichoposide
Page last updated: 2024-09-24

stichoposide

Description

stichoposide: triterpene glycoside; RN given refers to stichoposide A [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119095
MeSH IDM0042280

Synonyms (8)

Synonym
stichoposide a
stichoposide
holotoxins
lanost-7-en-18-oic acid, 23-(acetyloxy)-3-((2-o-(6-deoxy-beta-d-glucopyranosyl)-beta-d-xylopyranosyl)oxy)-20-hydroxy-, gamma-lactone, (3beta)-
2-{[2-o-(6-deoxyhexopyranosyl)pentopyranosyl]oxy}-18-oxo-18,20-epoxylanost-7-en-23-yl acetate
37341-37-0
[1-[15-[4,5-dihydroxy-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-2,6,13,17,17-pentamethyl-8-oxo-7-oxapentacyclo[10.8.0.02,9.05,9.013,18]icos-1(20)-en-6-yl]-4-methylpentan-2-yl] acetate
DTXSID60958457

Research Excerpts

Overview

ExcerptReference
"Stichoposide D (STD) is a marine triterpene glycoside isolated from sea cucumbers. "( Han, JY; Jeong, JS; Ju, MH; Kim, SH; Kwak, JY; Park, ES; Park, JI; Shin, SW; Stonik, VA; Yun, SH, 2015)

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (12.77)18.7374
1990's9 (19.15)18.2507
2000's15 (31.91)29.6817
2010's13 (27.66)24.3611
2020's4 (8.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.82%)5.53%
Reviews2 (3.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (94.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
glycosides[no description available]medium531
cdta[no description available]medium10organooxygen compound
beta-escin[no description available]medium70
holothurin[no description available]medium60
echinoside a[no description available]medium10
cucumarioside[no description available]medium10
4-carboxyfluorescein[no description available]medium10monocarboxylic acidfluorochrome
erythrosine[no description available]medium10
g(m1) ganglioside[no description available]medium20alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine;
sialotetraosylceramide
brefeldin a[no description available]medium10macrolide antibioticPenicillium metabolite
cycloheximide[no description available]medium10antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
interleukin-8[no description available]medium10
palmitic acid[no description available]medium10long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite
holothurin a[no description available]medium30
oleanolic acid[no description available]medium30hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
cauloside c[no description available]medium20triterpenoid
3-o-(alpha-l-arabinopyranosyl)hederagenin[no description available]medium10alpha-L-arabinopyranoside;
hydroxy monocarboxylic acid;
monosaccharide derivative;
pentacyclic triterpenoid;
triterpenoid saponin		plant metabolite
sapogenins[no description available]medium10
glucose, (beta-d)-isomer[no description available]medium10D-glucopyranoseepitope;
mouse metabolite
alanine[no description available]medium10alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
globotriaosylceramide[no description available]medium10
hydrogen sulfite[no description available]medium10sulfur oxoanionhuman metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ganglioside, gd1b[no description available]medium10
sulfites[no description available]medium10divalent inorganic anion;
sulfur oxide;
sulfur oxoanion
ganglioside, gd1a[no description available]medium10
calcimycin[no description available]medium10benzoxazole
ouabain[no description available]medium1011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
digoxin[no description available]medium10cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
contraceptives, postcoital[no description available]medium10
phosphatidylcholines[no description available]medium101,2-diacyl-sn-glycero-3-phosphocholine
5-doxylstearate[no description available]medium10aminoxyls
digitonin[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
African Lymphoma0low10
Body Weight0low10
Burkitt Cell Leukemia0low10
Burkitt Leukemia0low10
Burkitt Lymphoma0low10
Burkitt Tumor0low10
Burkitt's Leukemia0low10
Burkitt's Lymphoma0low10
Burkitt's Tumor0low10
Cancer of Cervix0low10
Cancer of Colon0low10
Cancer of the Cervix0low10
Cancer of the Colon0low10
Cancer of the Uterine Cervix0low10
Carcinoma, Ehrlich Tumor0low10
Cervical Cancer0low10
Cervical Neoplasms0low10
Cervix Cancer0low10
Cervix Neoplasms0low10
Colon Cancer0low10
Colon Neoplasms0low10
Colonic Cancer0low10
Colonic Neoplasms0low10
Colorectal Cancer0low10
Colorectal Carcinoma0low10
Colorectal Neoplasms0low10
Colorectal Tumors0low10
Disease Models, Animal0low10
E coli Infections0low10
E. coli Infection0low10
Ehrlich Ascites Tumor0low10
Escherichia coli Infections0low10
Experimental Neoplasms0low10
Extravascular Hemolysis0low10
Grippe0medium21
Haemolysis0low10
Hemolysis0low10
Human Flu0medium21
Human Influenza0medium21
Infections, E coli0low10
Infections, Escherichia coli0low10
Infections, Pneumovirus0low10
Influenza0medium21
Influenza in Humans0medium21
Influenza, Human0medium21
Intravascular Hemolysis0low10
Leucocythaemia0low30
Leucocythemia0low30
Leukemia0low30
Leukemia, Lymphoblastic, Burkitt-Type0low10
Leukemia, Lymphocytic, L30low10
Lymphocytic Leukemia, L30low10
Lymphoma, Burkitt0low10
Meningitis, Meningococcal0low10
Meningitis, Meningococcal, Serogroup A0low10
Meningitis, Meningococcal, Serogroup B0low10
Meningitis, Meningococcal, Serogroup C0low10
Meningitis, Meningococcal, Serogroup W-1350low10
Meningitis, Meningococcal, Serogroup W1350low10
Meningitis, Meningococcal, Serogroup Y0low10
Meningitis, Meningococcic0low10
Meningococcal Meningitis, Serogroup A0low10
Meningococcal Meningitis, Serogroup B0low10
Meningococcal Meningitis, Serogroup C0low10
Meningococcal Meningitis, Serogroup W-1350low10
Meningococcal Meningitis, Serogroup W1350low10
Meningococcal Meningitis, Serogroup Y0low10
Neoplasms, Cervical0low10
Neoplasms, Cervix0low10
Neoplasms, Colonic0low10
Neoplasms, Colorectal0low10
Neoplasms, Experimental0low10
Pneumovirus Infections0low10
Poisoning0low10
Sarcoma 370low10
Serogroup A Meningococcal Meningitis0low10
Serogroup B Meningococcal Meningitis0low10
Serogroup C Meningococcal Meningitis0low10
Serogroup W-135, Meningococcal Meningitis0low10
Serogroup W135, Meningococcal Meningitis0low10
Serogroup Y, Meningococcal Meningitis0low10
Uterine Cervical Cancer0low10
Uterine Cervical Neoplasms0low10

Research Highlights

Safety/Toxicity (1)

ArticleYear
Mouse toxicity and cytokine release by verotoxin 1 B subunit mutants.
Infection and immunity, Volume: 69, Issue: 1		2001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
Absorption and Transport of Sea Cucumber Saponins from Apostichopus japonicus.
Marine drugs, Jun-17, Volume: 14, Issue: 6		2016
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (2)

ArticleYear
[Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].
Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, Volume: 71, Issue: 2		1997
Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
Vaccine, Volume: 14, Issue: 2		1996
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]